Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: No discussion of the 890?

Adding to my post:

Historically, there has been no reporting of dollar amounts accompanying the news releases of the new licensees with the exceptions of a few initial signings. The license amounts are held until Q reporting.

I'm certain there was discussion of this here at the time that TPL/PTSC adopted the 'policy' of not reporting the license amounts at the time of the news release but I can't remember the consensus shared among posters. Can it be said that new licensees are considered non-material events by SEC standards?

TIA,

Regards,
PxP

Share
New Message
Please login to post a reply